Corticosteroid therapy in borderline tuberculoid leprosy patients co-infected with HIV undergoing reversal reaction: a clinical study.
Leprosy, caused by Mycobacterium leprae, and the human immunodeficiency virus (HIV) infection are two diseases that present major public health challenges. In 2013, there were 215,656 new leprosy cases detected worldwide. (1) In Brazil alone, there were 31,064 new cases in the following year. (2) In that same year internationally about 37 million people were infected by HIV (3) approximately 734,000 of whom were in Brazil. (4) The sheer magnitude of these stable detection rates for both diseases in recent years underscores the importance of more closely monitoring the occurrence of this co-infection.
According to the World Health Organization (WHO), Brazil is one of the few countries in which leprosy and AIDS are endemic. The Brazilian Ministry of Health offers free treatment for both diseases and plays an important role in the study of co-infected individuals. Unfortunately, there are still no available data from any previous studies regarding the prevalence and overall incidence of this kind of co-infection. (5)
During the clinical course of leprosy, patients may present with episodes of acute inflammation associated with altered immune responses. Referred to as reactional episodes, there are two distinct types: reversal reactions (RR) and erythema nodosum leprosum (ENL). Such reactions may occur before, during or after leprosy treatment. Reversal reactions are the leading cause of hospitalisation and are known to provoke the onset of life-long neurological sequelae. (6) While little is known about the influence of HIV infection on leprosy, it is believed that HIV infection may be the singular major risk factor in the development of reactional episodes, especially among paucibacillary patients. (7)
Some studies have recently demonstrated that after the introduction of highly active antiretroviral therapy (HAART), RR occurred as a manifestation of a new clinical presentation, called the immune reconstitution inflammatory syndrome (IRIS), (7-12) characterised by a high HIV viral load reduction and an increase in CD4 T cells. (7-12)
It has been surmised that HIV infection could exacerbate the pathogenesis of leprosy lesions, making them more severe, as shown in many case reports of co-infected patients presenting ulcerations during reversal reaction. (11-160 At the same time, it was likewise expected that HIV/M. leprae patients would present a more exuberant neurological clinical condition since the use of HAART and other medications commonly administered to HIV patients have been known to also lead to the development of peripheral neuropathy. (17,18)
Treatment of RR is aimed at controlling acute inflammation, relieving pain, and avoiding nerve damage. The use of corticosteroids to treat RR was first reported in 1952 (19) and, at that time, recommendations were made to start treatment as soon, and as cautiously, as possible, noting the potential for the development of opportunistic diseases and metabolic alterations. A number of later studies suggested that corticosteroid therapy might also benefit patients co-infected with HIV. (15,16,20,21) However, to date, there have been no published clinical studies on the co-infected. As a result, there is still no consensus on the optimal use of corticosteroids as to dosage, duration, and treatment safety with these patients.
In this study, we analysed HIV comorbidity with the borderline tuberculoid (BT) clinical form of leprosy (according to the classification of Ridley and Jopling (22)), which is the most prevailing clinical manifestation in co-infected patients in Brazil, as described in many reports. (7,10-12,16) Although the association between M. leprae and HIV infection may not have a direct impact on public health, (23) the clinical management and proper care of reactional states are extremely important to those most involved in this issue, and the community itself. The goal of this study is to evaluate and compare the epidemiological and clinical characteristics of BT patients with RR in HIV-positive and HIV-negative groups.
An analytical retrospective cohort study was carried out between January 1996 and September 2012 on the available medical records at the Souza Araujo Clinic (ASA) / Leprosy Laboratory (LAHAN)/Fiocruz, in the city of Rio de Janeiro.
Both male and female patients 15 years of age or older and undergoing regular multidrug therapy (MDT) for leprosy were included in the study. An analysis was made of the first RR episode (confirmed by histopathology) among the BT patients, who were divided up into two groups according to their serologic status for HIV infection: 1) an HIV/M. leprae co-infected group; and 2) an HIV-negative control group. HIV-infected patients were defined according to current Brazilian Ministry of Health guidelines. (24)
Epidemiological and clinical data were evaluated in two stages: the first involved the RR diagnosis itself; and the second was at the end of corticosteroid therapy (considering a cutoff of 6 months for those patients who had been administered corticosteroid therapy for a longer period of time) (Figure 1).
As the location of the research at hand is a national reference centre for the treatment of leprosy, the staff physicians are highly experienced and qualified in carrying out a rigorously thorough history and physical examination while being sensitive about detecting significant alterations in the development of the disease. As such, the following signs and symptoms were clinically and qualitatively assessed: loss of sensitivity (evaluated with an esthesiometer), lymphadenopathy, arthralgia, nerve pain, edema, weight loss, neural thickening, fever, malaise, myalgia, orchitis, paresthesia, hyperesthesia, and nasal and visual complaints. Furthermore, the number of affected body segments (head, anterior chest, posterior chest, right arm, left arm, abdomen, back, right leg, and left leg) was assayed; and the averages of these numbers were calculated for each group. Type of skin lesion, neuritis, degree of disability, and the Mitsuda test results (Figure 1) were also analysed.
Moreover, immunological status and the use of HAART and IRIS (according to the hallmarks described by Deps and Lockwood (12)) (Figure 1) were likewise evaluated. IRIS was defined as the presence of reaction at any time during the first 6 months of HAART together with a decrease of more than 1 log in the HIV-1 viral load and if a reaction occurs during the first 6 months of HAART in association with an undetectable HIV-1 viral load among naive patients with no laboratory test data.
Corticosteroid therapy was administered if a patient had begun prednisone at the beginning and/or end of MDT. Whether a patient needed corticosteroid therapy beyond the 6 months of the study (Figure 1) was also evaluated. For such patients, the observed dose was the one given during the sixth month of corticosteroid therapy, which was subdivided into three dosage groups, as follows: 0mg; from 5 mg to 15 mg; and 20 mg or more. Moreover, the total dosage averages (mg/kg/day) were calculated for both co-infected and non-co-infected groups and compared. Finally, the need for pulse therapy and/or hospitalisation was also reviewed.
Statistical analyses were performed using SPSS[R] version 16.0 software based on information regarding the variables stored on the above-mentioned database. Categorical variables were analysed using the chi-square test for Person or Fisher (to expected values of less than 5); and continuous variables were examined via the t-Student test, with a 5% statistically significant rate. Furthermore, analyses were performed by the logistic regression model to compare group variables in order to keep track of any interference of possibly confounding factors.
EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS
During the study period, 50 borderline tuberculoid patients were diagnosed with RR, 28 of whom were HIV-negative and 22 HIV-positive. A majority of patients in both groups was male (53% of the HIV-negative and 54% of the HIV-positive subjects). The average age of the control group was 38 (SD = 11.12) and that of the co-infected group was 40 (P = 0-657; SD = 12.33). Seventeen of the co-infected patients (77%) were on HAART, four (18%) were not in HIV treatment; and in one case (5%), this information was not registered. Most patients had CD4 > 200 cell/mm. (3) It is worth noting that six of the co-infected patients (27%) manifested RR as IRIS.
Upon a RR diagnosis, a great majority of patients presented skin lesion plaques (88%) followed by macules (14%) with no significant differences between the groups (P = 0-683 and P = 0.444 for plaque skin lesions and macules, respectively). Among the HIV-positive, ulcerated skin lesions were only observed in two IRIS patients (9%; P = 0.189). At the second stage of the RR evaluation, i.e., at the 6th month, macular lesions were more prevalent within the HIV-negative group (21%; P = 0.438) while plaque lesions were the most frequently found among the co-infected (17%; P = 0.915).
Neuritis was present in four within the control group (14%) and six among the co-infected patients (27%), P = 0.254 while most subjects in both groups had a disability grade of zero: 75% at baseline and 70% at the end of the review.
The average number of body segments affected by skin lesions was five (SD = 3.271) in the HIV-negative and four (SD = 3.075) in the HIV-positive groups at baseline (P = 0.157). In the end, the average was one segment in each group (SD = 2.231 among the controls and SD = 2.625 in the HIV/M. leprae group; P = 0.673).
The Mitsuda test results in both groups of patients were greater than or equal to 3 mm (67% HIV-negative and 77% HIV-positive patients; P = 0.462).
All variables had been considered in the statistical analysis, in Figure 2 are shown only the most prevalent clinical manifestations observed in both groups.
Among the signs and symptoms analysed at the end of the assessment, neural thickening (P = 0.024) and loss of sensitivity (P = 0.029) were considered statistically significant (Figure 2).
ANALYSES OF VARIABLES RELATED TO THE USE OF CORTICOSTEROIDS
It was observed that the majority of patients in both groups initiated MDT while undergoing reversal reaction (P = 0-919). At the end of MDT, about 62% of all patients were still using corticosteroids (Table 1).
The majority of both groups required an extension of the 6-month period; and no patient underwent pulse therapy for RR. Of the total 50 patients, only two HIV-positive ones required hospitalisation for RR clinical treatment.
Corticosteroid dosage at the 6th month of treatment did not differ between the groups, as can be seen in Table 1. The average total corticosteroid dosage within the HIV-negative and HIV-positive groups, respectively, was 0.4 mg/kg/day (SD = 0.12) and 0.5mg/kg/day (SD = 0.19), P = 0.102.
To date, there have been few published studies related to HIV-M. leprae co-infection. It was perhaps ultimately possible to gather together these 50 patients because both diseases are endemic in Rio de Janeiro. And ASA/LAHAN, a national reference centre for the treatment of co-infected patients, has a readily-available population at its disposal along with an extensive research database.
Some demographic characteristics described here such as average age and the higher proportion of men than women are similar to those examined in a number of other epidemiological studies conducted with co-infected patients in Brazil. (7,11,12,16,21,25,26)
Since the HIV virus affects cellular immunity and causes deficiencies in granuloma formation, a reduction in the response to the Mitsuda antigen in HIV-positive patients was expected, as demonstrated by other authors. (27) In the present work, among the HIV/M. leprae patients, the test remained positive, a fact also previously reported by other authors, (28) which is perhaps explicable by the preservation of a specific cellular immunity against M. leprae.
As treatment progressed, a cutback in the number of lesions in both groups was observed. Despite being uncommon in RR, in the present study, ulcerated lesions were only found among IRIS patients, also observed in other reports. (10,12,14,15) A reminder that detecting this kind of lesion is a procedure that must be conducted with caution; and the decision as to whether or not to extend the use of corticosteroid therapy should be taken with care.
It is assumed that HIV infection may aggravate the nerve damage caused by the bacillus in association with antiretroviral drug toxicity by causing a synergistic effect among these factors. This phenomenon has also been observed in other viral co-infections with leprosy, such as HTLV-1 and hepatitis B and C, and can change the host immunity, generating more severe neurological damage. (29)
In the present study, it is likewise noteworthy that most of the signs and symptoms of RR did not appear to be more severe among the co-infected patients. There did not seem to be any significant worsening in comparison to the uninfected, which has been verified by a number of other reports. (11,15,18,30-32) However, the neural thickening and loss of sensitivity detected in the final group evaluation were statistically significant. Nonetheless, some aspects of the immunopathological mechanisms involved in the interaction between M. leprae and HIV infection remain nebulous.
Overall, it was found that RR among the HIV-positive patients appeared to be slightly more neurologically compromised than the RR in their non-co-infected counterparts even though neuritis and degree of disability were similar in both groups. It is, of course, quite difficult to separate the synergy between the peripheral nerve involvement caused by M. leprae and the neuropathy associated with HIV and/or the effects of HAART.
After initiating HAART followed by the subsequent increase in CD4 T cells, RR may manifest as IRIS among the HIV-positive, (10-12,34,35) as was seen in the present study in which most patients were on HAART and had CD4 > 200 cell/mm. (3) In defining the moment this phenomenon takes place, Deps and Loockwood (12) suggested considering four different classifications. Nonetheless, immunological studies remain rare. Pires et al. (11) have found that 75% of BT patients developed RR as a manifestation of IRIS while, interestingly, our study found this same result in only six (27%) patients.
The major goals of any RR treatment are to control acute inflammation, relieve pain, and reverse nerve damage. Prednisone, which remains the drug of choice, including for co-infected patients, (10,11,16,35) must be administered immediately to avoid sequelae. (36-38) It is initially given in doses of 1-2 mg/kg/day and should be withdrawn only very gradually in all patients. (36-38)
Again, in the present study, both groups received similar doses of corticosteroids (an additional 0-1 mg/kg/day for the HIV-positive patients); and no statistically significant differences were found between the groups.
Pulse therapy is indicated for patients with an uncontrolled reactional condition. (37) In our cohort, no patient showed a need for pulse therapy. In some cases, a higher level of care is necessary such as hospitalisation to better control the effects of reaction, which in our case only occurred in two co-infected patients.
Sarno et al. (2008) showed that the HIV/M. leprae group manifested more reactions at diagnosis than the control group although both groups have had similar cumulative rates over time. The reason behind the increased frequency of reaction in co-infected patients is not yet clear but may be explained by the characteristic dysregulation of the immune system as a result of HIV infection. However, in the present study, most patients in both groups presented RR at the moment of diagnosis.
Regarding the duration of corticosteroid therapy, WHO recommends treating RR and neuritis for from 3-6 months in a specialised reference centre. (39) Again, most patients in the two groups continued corticosteroid therapy beyond the WHO-recommended 6 month period, indicating the need for continuity in treatment monitoring. It has been demonstrated that patients receiving a high initial dose of corticosteroid have fewer relapses and less nerve damage. (40) Nevertheless, it is important to emphasise that despite the high dosages still in use at the end of the present study, the need for a larger dose and prolonged treatment in some cases may have been influenced by the fact that ASA/LAHAN is a referral centre for the treatment of severe cases of reversal/neuritis reaction. Moreover, while corticosteroid is considered a mainstay in treating leprosy reaction, caution should be exercised so as to prevent any negligence or abuse. Prolonged use of these drugs may predispose patients to adverse events, opportunistic infections, and illnesses like diabetes, arterial hypertension, osteoporosis, glaucoma, and dermatological diseases. (15,41-44)
The major contribution of the present study was its novel approach to analysing a variety of data that made it possible to simultaneously compare RR in HIV-positive and HIV-negative patients. Most importantly, the results showed that corticosteroid therapy was effective in both these groups with major improvements in their cutaneous, systemic, and neural manifestations, particularly in comparison to their initial evaluations.
To conclude, it is our conviction that leprosy and HIV control programmes should be integrated to optimise the diagnosis, treatment, and care of co-infected patients. For this purpose, serologic tests for HIV could also be offered to RR patients. In addition, it should be emphasised that further studies aiming to better understand the epidemiological and clinical associations of these patients are a priority.
We would especially like to thank the National Council for Scientific and Technological Development (CNPq) for its financial support and Judy Grevan for editing the manuscript.
PJSA participated in the design of the study, carried out data acquisition, and drafted the manuscript. MAVBH performed the statistical analysis. AMS, JACN and VMM reviewed the medical content of the text. FDG helped draft the manuscript; and ENS participated in its design and coordination. All authors contributed to the writing of the final manuscript; and all have read and approved it.
The author(s) declare that they have no competing interests.
(1) World Health Organization. Weekly Epidemiological Record: Releve Epidemiologique Hebdomadaire, 2013; 8: 365-380.
(2) Ministerio da Saiide do Brasil. Situacao Epidemiologica de Hanseniase no Brasil em 2014. [http://portalsaude. saude.gov.br/images/pdf/2015/julho/27/Dados-2014-final.pdf]. Accessed November 01, 2015.
(3) World Health Organization. HIV/AIDS. [http://www.who.int/hiv/data/epi_core_july2015.png?ua = 1]. Accessed October 17, 2015.
(4) Ministerio da Saude do Brasil. Boletim Epidemiologico-Aids e DST. [http://www.aids.gov.br/sites/default/files/ anexos/publicacao/2014/56677/boletim_2014_final_pdf_15565.pdf]. Accessed November 11, 2015.
(5) Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS, 2013. According to the UNAIDS' estimate the number of new infections in the region increased from, 21, 22-000.
(6) Nery JAC, Dupre NC, Sales AM et al. Contributo ao diagnostico e manejo dos estados reacionais. Uma abordagem pratica. An Bras Dermatol, 2006; 81: 367-375.
(7) Sarno EN, Illarramendi X, Nery JA et al. HIV-M. leprae interaction: can HAART modify the course of leprosy? Public Health Rep, 2008; 123: 206-212.
(8) Couppie P, Domergue V, Clyti E et al. Increased incidence of leprosy following HAART initiation: a manifestation of the immune reconstitution disease. AIDS, 2009; 23: 1599-1600.
(9) Vinay K, Smita J, Nikhil G, Neeta G. Human immunodeficiency virus and leprosy co-infection in Pune, India. J Clin Microbiol, 2009; 47: 2998-2999.
(10) Menezes VM, Sales AM, Nery JAC, et al. Reversal reaction as a manifestation of immune reconstitution inflammatory syndrome in HIV/M. leprae co-infected patients. In Dr. Yi-Wei-Tang. Recent Translational Research in HIV/AIDS 2011, In Tech, Croatia, p. 161-176.
(11) Pires CAA, Neto FOMJ, de Albuquerque NC et al. Leprosy reactions in patients coinfected with HIV: clinical aspects and outcomes in two comparative cohorts in the Amazon region, Brazil. PLoS Negl Trop Dis, 2015; 9: e0003818.
(12) Deps P, Lockwood DN. Leprosy presenting as immune reconstitution inflammatory syndrome: proposed definitions and classification. Lepr Rev, 2010; 81: 59.
(13) Opromolla DVA, Ura S, Fleury RN et al. Reacao Hansenica Tipo 1 Ulcerada. Hansen. Int, 1998; 23(1/2): 5-13.
(14) Couppie P, Abel S, Voinchet H et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Archives of dermatology, 2004; 140: 997.
(15) Lockwood DN, Lambert SM. Leprosy and HIV, where are we at? Lepr Rev, 2010; 81: 169-175.
(16) Talhari C, Mira MT, Massone C et al. Leprosy and HIV co-infection: a clinical, pathological, immunological, and therapeutic study of a cohort from a Brazilian referral center for infectious diseases. J Infect Dis, 2010; 202: 345-354.
(17) Carr A, Cooper DA. Adverse effects of antiretroviral therapy. The Lancet, 2000; 356(9239): 1423-1430.
(18) Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. Journal of the Peripheral Nervous System, 2001; 6: 21-27.
(19) Lowe J. A.C.T.H. and cortisone in treatment of complications of leprosy. Br Med J, 1952; 2(4787): 746-749.
(20) Bwire R, Kawuma HJ. Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Trans R Soc Trop Med Hyg, 1994; 88: 315-316.
(21) Pereira GA, Stefani MM, Araujo Filho JA et al. Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium leprae co-infection: HIV-1 subtypes and clinical, immunologic, and histopathologic profiles in a Brazilian cohort. Am J Trop Med Hyg, 2004; 71: 679-684.
(22) Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other MycobactDis, 1966; 34: 255-273.
(23) Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis, 2006; 6: 350-360.
(24) Ministerio da Saiide. Secretaria de Vigilancia em Saude. Departamento de DST, AIDS e Hepatites Virais. Protocolo Clinico e Diretrizes Terapeuticas para Adultos Vivendo com HIV/AIDS. 2013b; Brasilia.
(25) Pires CAA, Miranda MFRD, Bittencourt MDJS et al. Comparison between histopathologic features of leprosy in reaction lesions in HIV coinfected and non-coinfected patients*. An Bras Dermatol, 2015; 90: 27-34.
(26) Menezes VM, Nery JAC, Vendas AM, et al. Epidemiologica e padroes clinicos de 92 pacientes co-infectados com HIV e Mycobacterium leprae a partir do Estado do Rio de Janeiro, Brasil. Transactions of The Royal Society of Tropical Medicine and Hygiene 2013; trt113.
(27) Pereira AC, Jr, Caneschi JR, Azulay MM et al. O estudo da resposta imune em pacientes com infeccao pelo virus da imunodeficiencia humana (HIV) em relacao ao antigeno de Mitsuda. An Bras Dermatol, 1992; 67: 97-102.
(28) Ura S, Girao RJS, Opromolla DVA et al. Hanseniase tuberculoide em paciente com AIDS. Hansen. Int, 2004; 29: 137-140.
(29) Machado PRL, Machado LM, Shibuya M et al. Viral co-infection and leprosy outcomes: a cohort study. PLoS Negl Trop Dis, 2015; 9: e0003865.
(30) Frommel D, Tekle-Haimanot R, Verdier M et al. HIV infection and leprosy: a four-year survey in Ethiopia. Lancet, 1994; 344(8916): 165-166.
(31) Munyao TM, Bwayo JJ, Owili DM et al. Human immunodeficiency virus- 1 in leprosy patients attending Kenyatta National Hospital, Nairobi. East Afr Med J, 1994; 71: 490-492.
(32) Gebre S, Saunderson P, Messele T, Byass P. The effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia. Lepr Rev, 2000; 71: 338-343.
(33) Opromolla DVA, Tonello CJS, Fleury RN. Hanseniase dimorfa e infeccao pelo HIV (aids). Hansen int, 2000; 25: 54-59.
(34) Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis, 2003; 36: e5-e6.
(35) Menezes VM, Sales AM, Illarramendi X et al. Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort. Aids, 2009; 23: 641-643.
(36) Smith WCS, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD1). BMJ, 2004; 328(7454): 1459.
(37) Ministerio da Saude do Brasil. Orientacoes para uso Corticoides em Hanseniase. [http://www.saude.gov.br/bvs]. Accessed November 7, 2014.
(38) Ministerio da Saude do Brasil. Guia para o Controle da Hanseniase. 2002; 3aed.Brasilia.
(39) World Health Organization. Global Strategy for further reducing the leprosy burden and sustaining leprosy control activities: plan period: 2006-2010. 2005.
(40) Pai VV, Tayshetye PU, Ganapati R. A study of standardized regimens of steroid treatment in reactions in leprosy at a referral centre. Indian J Lepr, 2012; 84: 9-15.
(41) Sugumaran DS. Leprosy reactions-complications of steroid therapy. Int J Lepr Other Mycobact Dis, 1998; 66: 10-15.
(42) van Brakel WH, Nicholls PG, Das L et al. The INFIR cohort study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev, 2005; 76: 14-34.
(43) Walker SL, Lockwood DNJ. Leprosy Type 1 (reversal) reactions and their management. Lepr Rev, 2008; 79: 372-386.
(44) Papang R, John AS, Abraham S, Rao PSSS. A study of steroid-induced diabetes mellitus in leprosy. Indian J Lepr, 2009; 81: 125-129.
PEDRO JOSE SECCHIN-DE-ANDRADE *, MARIANA DE ANDREA VILAS-BOAS HACKER *, ANNA MARIA SALES*, FELIPE DALVI-GARCIA **, JOSE AUGUSTO DA COSTA NERY *, VINICIUS MARTINS MENEZES * & EUZENIR NUNES SARNO *
* Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Leprosy Laboratory, Rio de Janeiro, RJ, Brazil
** Bioinformatics Lab, National Laboratory for Scientific Computing, Petropolis, RJ, Brazil
Accepted for publication 5 October 2016
Correspondence to: Pedro Jose Secchin-de-Andrade, Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, Brazil 21040-360 (Tel: + 55 21 2562 1527; e-mail: firstname.lastname@example.org)
Caption: Figure 1. Study design and clinical course of the RR.
Caption: Figure 2. Initial and final evaluation of the main signs and symptoms of RR.
Table 1. Evaluation of the use of corticosteroids HIV Negative Positive Characteristics N/Nn (% *) N/Np (% *) MDT initiated with 20/28 (71.4) 16/22 (72.7) corticosteroids MDT ending with 17/28 (60.7) 14/22 (63.6) corticosteroids Corticosteroids used for 18/28 (64.3) 14/22 (63.6) more than 6 months Dosage of corticosteroid 0 mg 10/28 (35.7) 8/22 (36.4) at the 6th month 5 mg to 15 mg 12/28 (42.9) 8/22 (36.4) 20 mg or more 6/28 (21.4) 6/22 (27.3) Total Characteristics N/Nt (% *) P value MDT initiated with 36/50 (72) 0.919 corticosteroids MDT ending with 31/50 (62) 0.833 corticosteroids Corticosteroids used for 32/50 (64) 0.962 more than 6 months Dosage of corticosteroid 0 mg 18/50 (36) at the 6th month 5 mg to 15 mg 20/50 (40) 0.858 20 mg or more 12/50 (24) (*) Percentage of the valid total. N: number of patients; Nn: total number of HIV-negative patients; Np: total number of HIV-positive patients; Nt: total number of patients.
|Printer friendly Cite/link Email Feedback|
|Author:||Secchin-De-Andrade, Pedro Jose; Vilas-Boas Hacker, Mariana De Andrea; Sales, Anna Maria; Dalvi-Garci|
|Date:||Dec 1, 2016|
|Previous Article:||TlyA protein of mycobacterium leprae: a probable bio-marker of active infection.|
|Next Article:||Lucio phenomenon of leprosy LL type on pregnancy: a rare case.|